Loading…
Loading…
EQUITY / NASDAQ · XNCM
Sunshine Biopharma Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.6665 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 0.6665 USD · Volume 149,383
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | Prior year | Change |
|---|---|---|---|
| Revenue | 9,263,687 USD | — | — |
| Operating profit | -1,612,858 USD | — | — |
| Net income | -1,564,048 USD | — | — |
| Total liabilities | 6,094,899 USD | — | — |
| Total equity | 27,538,002 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 203/31/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 101/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Gross profitIncome statement | 2,426,682 USD | 4,607,672 USD | — | 2,180,990 USD | — | 12,255,677 USD | 3,073,540 USD | 9,226,832 USD |
| Net incomeIncome statement | -1,564,048 USD | -2,807,917 USD | — | -1,243,869 USD | — | -5,975,352 USD | -883,820 USD | -3,834,425 USD |
| Operating profitIncome statement | -1,612,858 USD | -3,008,455 USD | — | -1,395,597 USD | — | -6,227,029 USD | -1,086,613 USD | -4,437,018 USD |
| RevenueIncome statement | 9,263,687 USD | 17,352,452 USD | — | 8,088,765 USD | — | 36,305,891 USD | 9,417,179 USD | 27,728,750 USD |
| Total assetsBalance sheet | 33,632,901 USD | — | — | 27,930,375 USD | 30,079,167 USD | 30,079,167 USD | 31,487,379 USD | — |
| Total equityBalance sheet | 27,538,002 USD | — | 21,516,594 USD | 21,516,594 USD | 23,038,460 USD | 23,038,460 USD | 24,199,356 USD | — |
| Total liabilitiesBalance sheet | 6,094,899 USD | — | — | 6,413,781 USD | 7,040,707 USD | 7,040,707 USD | 7,288,023 USD | — |
| Capital expendituresCash flow statement | — | 12,144 USD | — | 5,129 USD | — | 174,491 USD | — | 175,530 USD |
| Financing cash flowCash flow statement | — | 7,804,185 USD | — | 0 USD | — | 4,748,408 USD | — | 4,023,908 USD |
| Investing cash flowCash flow statement | — | -109,638 USD | — | -104,518 USD | — | -836,306 USD | — | -786,097 USD |
| Operating cash flowCash flow statement | — | -2,990,077 USD | — | -2,072,100 USD | — | -5,331,073 USD | — | -3,715,067 USD |
| Report source | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 05/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 04/03/2026 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 11/13/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.